Page last updated: 2024-12-07

flosequinoxan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

flosequinoxan: metabolite of BTS 49465 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID131270
SCHEMBL ID6050597
MeSH IDM0136721

Synonyms (14)

Synonym
7-fluoro-1-methyl-3-methylsulfonyl-4-quinolone
bts-53554
bts 53554
4(1h)-quinolinone, 7-fluoro-1-methyl-3-(methylsulfonyl)-
flosequinoxan
76568-68-8
AKOS005766017
7-fluoro-1-methyl-3-methylsulfonylquinolin-4-one
GE-0007
SCHEMBL6050597
ZUMVHPMHCIKNFT-UHFFFAOYSA-N
7-fluoro-1-methyl-3-methylsulphonyl-4-quinolone
7-fluoro-3-(methanesulfonyl)-1-methylquinolin-4(1h)-one
DTXSID90997910

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" All 10 patients provided analyzable data even though one patient withdrew before the 144-h sample because of an adverse event unrelated to the study medication."( Pharmacokinetics, safety, and tolerability of flosequinan in patients with hepatic dysfunction.
Hind, ID; Hinson, JL; Weidler, DJ, 1994
)
0.29

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic and haemodynamic effects of a 200 mg oral dose of BTS 49 465 (7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone) were investigated in a double-blind placebo controlled study."( The pharmacokinetics and haemodynamics of BTS 49 465 and its major metabolite in healthy volunteers.
Crampton, EL; Hind, ID; Wynne, RD, 1985
)
0.27
" Interpatient variability was appreciable for the plasma and urine concentrations was well as for the calculated pharmacokinetic parameters."( Pharmacokinetics, safety, and tolerability of flosequinan in patients with hepatic dysfunction.
Hind, ID; Hinson, JL; Weidler, DJ, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (9.09)18.7374
1990's10 (90.91)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (18.18%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (81.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]